Piper Jaffray lowers its rating on Seattle Genetics SGEN from Neutral to Underweight and reduces its price target from $22 to $20.
Piper Jaffray comments, "Seattle Genetics launched a great drug ADCETRIS for Hodgkin's lymphoma, has strong corporate partnerships and a healthy balance sheet. But SGEN is an expensive stock trading at >20x ADCETRIS sales. We presently forecast sales of $142.4 million this year and $140 million in 2013. We do not expect to see meaningful sales growth until data supports earlier utilization of ADCETRIS in Hodgkins/ALCL or other CD-30+ cancers. We recommend investors take profits at current levels."
SGEN closed at $25.39 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in